<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406649</url>
  </required_header>
  <id_info>
    <org_study_id>STS101-003</org_study_id>
    <nct_id>NCT04406649</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine</brief_title>
  <acronym>ASCEND</acronym>
  <official_title>An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Satsuma Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Satsuma Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study STS101-003 is a multi-center, multiple dose (PRN), open-label, 12-month study to&#xD;
      evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute&#xD;
      treatment of migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ASCEND trial is a multi-center, multiple dose (PRN), open-label, 12-month study to&#xD;
      evaluate the safety and tolerability of STS101 (dihydroergotamine nasal powder) in the acute&#xD;
      treatment of migraine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Incidence of adverse events, incidence of abnormal physical examination findings, abnormal 12-lead ECG readings and incidence of nasal symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Freedom</measure>
    <time_frame>Up to 48 hours post-dosing</time_frame>
    <description>Proportion of subjects free from headache pain (defined as moderate or severe headache pain becoming none on a 4-point scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Most-Bothersome Symptom</measure>
    <time_frame>Up to 48 hours post-dosing</time_frame>
    <description>Proportion of subjects free from most bothersome symptom (MBS) among photophobia, phonophobia and nausea</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Migraine</condition>
  <condition>Migraine With Aura</condition>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>STS101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STS101 (dihydroergotamine nasal powder)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydroergotamine</intervention_name>
    <description>Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.</description>
    <arm_group_label>STS101</arm_group_label>
    <other_name>Dihydroergotamine Mesylate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, 18-65 years of age at the time of Screening Visit&#xD;
&#xD;
          -  Subject has at least 1-year history of migraines (with or without aura), according to&#xD;
             the&#xD;
&#xD;
          -  International Classification of Headache Disorder, 3rd Edition (ICHD3)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Women of child-bearing potential not using or not willing to use highly effective&#xD;
             contraception.&#xD;
&#xD;
          -  Diagnosis of headache conditions other than migraine with or without aura, including&#xD;
             diagnosis of basilar or hemiplegic migraines or cluster headache.&#xD;
&#xD;
          -  History of coronary artery disease, coronary artery vasospasm (including&#xD;
             Printz-metals' angina), clinically significant arrhythmia or, peripheral vascular&#xD;
             disease, ischemic disease (e.g. Raynaud's syndrome, ischemic bowel syndrome, angina&#xD;
             pectoris, myocardial infarction, or documented silent ischemia); percutaneous coronary&#xD;
             intervention, or cardiac surgery.&#xD;
&#xD;
          -  History of cerebrovascular disease, including but not limited to stroke, transient&#xD;
             ischemic attack, cerebral hemorrhage, subarachnoid hemorrhage.&#xD;
&#xD;
          -  Diagnosis of major depression with current symptoms, psychosis, alcohol abuse or&#xD;
             dependence, drug abuse or dependence, major psychiatric conditions (e.g.&#xD;
             schizophrenia, psychosis or Bipolar disorder), dementia. Other significant&#xD;
             neurological or psychiatric disorders (including other pain syndromes or risk of&#xD;
             suicide) that in the opinion of the investigator might interfere with study&#xD;
             participation and assessments or subject safety.&#xD;
&#xD;
          -  Any clinically significant symptoms or conditions, including but not limited to&#xD;
             central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic&#xD;
             or gastrointestinal conditions or history of such conditions that, in the opinion of&#xD;
             the investigator might interfere with study assessments or safety of participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Detlef Albrecht, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Satsuma Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>6508370799</phone>
    <email>clin.inquiries@satsumarx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WR-PRI</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Vuong</last_name>
      <phone>818-705-7450</phone>
      <email>jvuong@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Grosz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>WR-PRI</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Delgado</last_name>
      <phone>714-827-3668</phone>
      <email>adelgado@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Downtown LA Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Cisneros</last_name>
      <phone>213-261-3680</phone>
      <email>ccisneros@dtlaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Salil Nadkarni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>WR-PRI</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hillcrest Medical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Hammerle</last_name>
      <phone>321-999-7616</phone>
      <email>angelah@hillcrestmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>John Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lazaro Gonzalez</last_name>
      <phone>954-455-5757</phone>
      <email>lgonzalez@mdclinical.org</email>
    </contact>
    <investigator>
      <last_name>Beth Safirstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber R Tompkins-Cordero</last_name>
      <phone>386-438-8977</phone>
      <email>amber@msrainc.com</email>
    </contact>
    <investigator>
      <last_name>Guy Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinCloud</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jawad Alqerem</last_name>
      <phone>407-590-3944</phone>
    </contact>
    <investigator>
      <last_name>Esteban Olivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Behavioral Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessmin Richani</last_name>
      <phone>305-722-8444</phone>
      <phone_ext>2244</phone_ext>
      <email>jrichani@segaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Olga Lapeyra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biotech Pharmaceuticals</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Manzano</last_name>
      <phone>305-667-8434</phone>
      <email>c26applemed@aol.com</email>
    </contact>
    <investigator>
      <last_name>Enrique De La Torre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CNS Health Care - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complete Health Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Evans</last_name>
      <phone>386-236-2456</phone>
      <email>kevans@completehealthresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Carpenter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santos Research Center, Corp</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odarkys Rodriguez</last_name>
      <phone>813-249-9100</phone>
      <email>odarkysresearchcenter@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sherley R Valdez-Arroyo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Segalis</last_name>
      <phone>561-689-0606</phone>
      <email>mary@palmbeachresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mira Baron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research CF</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Integrated Clinical Trial Services, Inc</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Simpson</last_name>
      <phone>515-223-2300</phone>
      <email>ssimpson@ictsiowa.com</email>
    </contact>
    <investigator>
      <last_name>Kathleen Gannon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delricht Research</name>
      <address>
        <city>Prairieville</city>
        <state>Louisiana</state>
        <zip>70769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Bolton</last_name>
      <phone>225-412-0316</phone>
      <email>bbolton@delricht.com</email>
    </contact>
    <investigator>
      <last_name>Taylor Sanders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvadis Research at Boston PainCare Center</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica O'Brien</last_name>
      <phone>781-895-7942</phone>
      <email>jeobrien@medvadis.com</email>
    </contact>
    <investigator>
      <last_name>David DiBenedetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <zip>63042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndsay Goeke</last_name>
      <phone>314-972-9600</phone>
      <email>lgoeke@healthcareresearchnetwork.com</email>
    </contact>
    <investigator>
      <last_name>Larry Reed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinvest Research</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dillon McLeod</last_name>
      <phone>406-549-1124</phone>
      <email>adeleon@crcnnv.com</email>
    </contact>
    <investigator>
      <last_name>Clancy Cone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research - Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Deleon</last_name>
      <phone>702-893-8968</phone>
      <email>adeleon@crcnnv.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Neurology Headache Clinic</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Polidor</last_name>
      <phone>603-650-5214</phone>
      <email>Jeffrey.R.Polidor@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Nye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Brunet-Lecomte</last_name>
      <phone>505-224-7407</phone>
      <phone_ext>241</phone_ext>
      <email>kbrunet@abqct.com</email>
    </contact>
    <investigator>
      <last_name>Merigene Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Sun</last_name>
      <phone>718-405-8360</phone>
    </contact>
    <investigator>
      <last_name>Richard Lipton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Research</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Gutkin</last_name>
      <phone>718-616-2249</phone>
      <email>jgutkin@spristudy.com</email>
    </contact>
    <investigator>
      <last_name>Nick Vatakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Nogues</last_name>
      <phone>336-574-8020</phone>
      <email>tnogues@pharmquest.biz</email>
    </contact>
    <investigator>
      <last_name>Alexander Murray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Hendy</last_name>
      <phone>513-753-4374</phone>
      <email>khendy@ctifacts.com</email>
    </contact>
    <investigator>
      <last_name>James Maynard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neurology Diagnosis</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasnim Kamil</last_name>
      <phone>973-224-8200</phone>
      <phone_ext>112</phone_ext>
      <email>tasnim.Kamil@neurologydiagnostics.com</email>
    </contact>
    <investigator>
      <last_name>Joel Vandersluis, D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delricht Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall Morris</last_name>
      <phone>918-932-2276</phone>
      <email>mmorris@delricht.com</email>
    </contact>
    <investigator>
      <last_name>Melita Tate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University/Jefferson Headache Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hopkins</last_name>
      <phone>215-955-2727</phone>
      <email>mary.hopkins@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>William Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare - Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra O'Brien</last_name>
      <phone>901-843-1045</phone>
      <phone_ext>513</phone_ext>
      <email>dobrien@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Lora McGill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Gonzales</last_name>
      <phone>281-517-0550</phone>
      <email>vgonzales@dmclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Muhammad Irfan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital, Department of Neurology</name>
      <address>
        <city>McLean</city>
        <state>Virginia</state>
        <zip>22101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Gough</last_name>
      <phone>703-288-9771</phone>
      <email>ccg46@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Ailani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dihydroergotamine</keyword>
  <keyword>dihydroergotamine mesylate</keyword>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroergotamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

